Cargando…

Siropins, novel serine protease inhibitors from gut microbiota acting on human proteases involved in inflammatory bowel diseases

BACKGROUND: In eukaryotes, the serpins constitute a wide family of protease inhibitors regulating many physiological pathways. Many reports stressed the key role of serpins in several human physiopathologies including mainly the inflammatory bowel diseases. In this context, eukaryotic serpins were l...

Descripción completa

Detalles Bibliográficos
Autores principales: Mkaouar, Héla, Akermi, Nizar, Mariaule, Vincent, Boudebbouze, Samira, Gaci, Nadia, Szukala, Florette, Pons, Nicolas, Marquez, Josan, Gargouri, Ali, Maguin, Emmanuelle, Rhimi, Moez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127057/
https://www.ncbi.nlm.nih.gov/pubmed/27894344
http://dx.doi.org/10.1186/s12934-016-0596-2
_version_ 1782470205236051968
author Mkaouar, Héla
Akermi, Nizar
Mariaule, Vincent
Boudebbouze, Samira
Gaci, Nadia
Szukala, Florette
Pons, Nicolas
Marquez, Josan
Gargouri, Ali
Maguin, Emmanuelle
Rhimi, Moez
author_facet Mkaouar, Héla
Akermi, Nizar
Mariaule, Vincent
Boudebbouze, Samira
Gaci, Nadia
Szukala, Florette
Pons, Nicolas
Marquez, Josan
Gargouri, Ali
Maguin, Emmanuelle
Rhimi, Moez
author_sort Mkaouar, Héla
collection PubMed
description BACKGROUND: In eukaryotes, the serpins constitute a wide family of protease inhibitors regulating many physiological pathways. Many reports stressed the key role of serpins in several human physiopathologies including mainly the inflammatory bowel diseases. In this context, eukaryotic serpins were largely studied and their use to limit inflammation was reported. In comparison to that, bacterial serpins and mainly those from human gut microbiota remain poorly studied. RESULTS: The two genes encoding for putative serpins from the human gut bacterium Eubacterium sireaum, display low sequence identities. These genes were overexpressed and the encoded proteins, named Siropins, were purified. Activity studies demonstrated that both purified proteins inhibited serine proteases but surprisingly they preferentially inhibited two human serine proteases (Human Neutrophil Elastase and Proteinase3). The biochemical characterization of these Siropins revealed that Siropin 1 was the most active and stable at low pH values while Siropin 2 was more thermoactive and thermostable. Kinetic analysis allowed the determination of the stoichiometry of inhibition (SI) which was around 1 and of the association rate constants of 7.7 × 10(4) for the Human Neutrophil Elastase and 2.6 × 10(5) for the Proteinase3. Moreover, both Siropins displayed the ability to inhibit proteases usually present in fecal waters. Altogether our data indicate the high efficiency of Siropins and their probable involvement in the control of the overall intestine protease activity. CONCLUSIONS: Here we report the purification and the biochemical characterization of two novel serpins originated from Eubacterium sireaum, a human gastro-intestinal tract commensal bacteria. These proteins that we called Siropins, efficiently inhibited two human proteases reported to be associated with inflammatory bowel diseases. The determination of the biochemical properties of these enzymes revealed different temperature and pH behaviours that may reflect adaptation of this human commensal bacterium to different ecological environments. To the best of our knowledge, it is the first bacterial serpins showing an attractive inhibition of fecal proteases recovered from a mice group with chemically induced inflammation. Altogether our data highlight the interesting potential of Siropins, and serpins from the human gut microbiota in general, to be used as new alternative to face inflammatory diseases. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12934-016-0596-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5127057
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51270572016-12-08 Siropins, novel serine protease inhibitors from gut microbiota acting on human proteases involved in inflammatory bowel diseases Mkaouar, Héla Akermi, Nizar Mariaule, Vincent Boudebbouze, Samira Gaci, Nadia Szukala, Florette Pons, Nicolas Marquez, Josan Gargouri, Ali Maguin, Emmanuelle Rhimi, Moez Microb Cell Fact Research BACKGROUND: In eukaryotes, the serpins constitute a wide family of protease inhibitors regulating many physiological pathways. Many reports stressed the key role of serpins in several human physiopathologies including mainly the inflammatory bowel diseases. In this context, eukaryotic serpins were largely studied and their use to limit inflammation was reported. In comparison to that, bacterial serpins and mainly those from human gut microbiota remain poorly studied. RESULTS: The two genes encoding for putative serpins from the human gut bacterium Eubacterium sireaum, display low sequence identities. These genes were overexpressed and the encoded proteins, named Siropins, were purified. Activity studies demonstrated that both purified proteins inhibited serine proteases but surprisingly they preferentially inhibited two human serine proteases (Human Neutrophil Elastase and Proteinase3). The biochemical characterization of these Siropins revealed that Siropin 1 was the most active and stable at low pH values while Siropin 2 was more thermoactive and thermostable. Kinetic analysis allowed the determination of the stoichiometry of inhibition (SI) which was around 1 and of the association rate constants of 7.7 × 10(4) for the Human Neutrophil Elastase and 2.6 × 10(5) for the Proteinase3. Moreover, both Siropins displayed the ability to inhibit proteases usually present in fecal waters. Altogether our data indicate the high efficiency of Siropins and their probable involvement in the control of the overall intestine protease activity. CONCLUSIONS: Here we report the purification and the biochemical characterization of two novel serpins originated from Eubacterium sireaum, a human gastro-intestinal tract commensal bacteria. These proteins that we called Siropins, efficiently inhibited two human proteases reported to be associated with inflammatory bowel diseases. The determination of the biochemical properties of these enzymes revealed different temperature and pH behaviours that may reflect adaptation of this human commensal bacterium to different ecological environments. To the best of our knowledge, it is the first bacterial serpins showing an attractive inhibition of fecal proteases recovered from a mice group with chemically induced inflammation. Altogether our data highlight the interesting potential of Siropins, and serpins from the human gut microbiota in general, to be used as new alternative to face inflammatory diseases. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12934-016-0596-2) contains supplementary material, which is available to authorized users. BioMed Central 2016-11-29 /pmc/articles/PMC5127057/ /pubmed/27894344 http://dx.doi.org/10.1186/s12934-016-0596-2 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Mkaouar, Héla
Akermi, Nizar
Mariaule, Vincent
Boudebbouze, Samira
Gaci, Nadia
Szukala, Florette
Pons, Nicolas
Marquez, Josan
Gargouri, Ali
Maguin, Emmanuelle
Rhimi, Moez
Siropins, novel serine protease inhibitors from gut microbiota acting on human proteases involved in inflammatory bowel diseases
title Siropins, novel serine protease inhibitors from gut microbiota acting on human proteases involved in inflammatory bowel diseases
title_full Siropins, novel serine protease inhibitors from gut microbiota acting on human proteases involved in inflammatory bowel diseases
title_fullStr Siropins, novel serine protease inhibitors from gut microbiota acting on human proteases involved in inflammatory bowel diseases
title_full_unstemmed Siropins, novel serine protease inhibitors from gut microbiota acting on human proteases involved in inflammatory bowel diseases
title_short Siropins, novel serine protease inhibitors from gut microbiota acting on human proteases involved in inflammatory bowel diseases
title_sort siropins, novel serine protease inhibitors from gut microbiota acting on human proteases involved in inflammatory bowel diseases
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127057/
https://www.ncbi.nlm.nih.gov/pubmed/27894344
http://dx.doi.org/10.1186/s12934-016-0596-2
work_keys_str_mv AT mkaouarhela siropinsnovelserineproteaseinhibitorsfromgutmicrobiotaactingonhumanproteasesinvolvedininflammatoryboweldiseases
AT akerminizar siropinsnovelserineproteaseinhibitorsfromgutmicrobiotaactingonhumanproteasesinvolvedininflammatoryboweldiseases
AT mariaulevincent siropinsnovelserineproteaseinhibitorsfromgutmicrobiotaactingonhumanproteasesinvolvedininflammatoryboweldiseases
AT boudebbouzesamira siropinsnovelserineproteaseinhibitorsfromgutmicrobiotaactingonhumanproteasesinvolvedininflammatoryboweldiseases
AT gacinadia siropinsnovelserineproteaseinhibitorsfromgutmicrobiotaactingonhumanproteasesinvolvedininflammatoryboweldiseases
AT szukalaflorette siropinsnovelserineproteaseinhibitorsfromgutmicrobiotaactingonhumanproteasesinvolvedininflammatoryboweldiseases
AT ponsnicolas siropinsnovelserineproteaseinhibitorsfromgutmicrobiotaactingonhumanproteasesinvolvedininflammatoryboweldiseases
AT marquezjosan siropinsnovelserineproteaseinhibitorsfromgutmicrobiotaactingonhumanproteasesinvolvedininflammatoryboweldiseases
AT gargouriali siropinsnovelserineproteaseinhibitorsfromgutmicrobiotaactingonhumanproteasesinvolvedininflammatoryboweldiseases
AT maguinemmanuelle siropinsnovelserineproteaseinhibitorsfromgutmicrobiotaactingonhumanproteasesinvolvedininflammatoryboweldiseases
AT rhimimoez siropinsnovelserineproteaseinhibitorsfromgutmicrobiotaactingonhumanproteasesinvolvedininflammatoryboweldiseases